Director's Dealing • Jan 18, 2023
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 1286N
Hikma Pharmaceuticals Plc
18 January 2023
Notification and public disclosure of transactions by persons discharging managerial responsibilities
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Deneen Vojta |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Market purchase of 1000 Ordinary Shares |
| c) | Price(s) and volume(s) | Price(s): £17.02676 Volume(s):1000 |
| d) | Aggregated information - Volume - Price - Total |
1000 £17.02676 £17,026.76 |
| e) | Date of the transaction | 17 January 2023 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Helen Middlemist, Deputy Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
18 January 2023
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBGGDBGBBDGXI
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.